Primavera Alessandra Spagnolo, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Alcoholism | 9 | 2022 | 1906 | 1.760 |
Why?
|
Conversion Disorder | 2 | 2023 | 205 | 1.280 |
Why?
|
Transcranial Magnetic Stimulation | 7 | 2022 | 1432 | 1.260 |
Why?
|
Movement Disorders | 2 | 2021 | 445 | 1.170 |
Why?
|
Behavior, Addictive | 5 | 2019 | 462 | 0.910 |
Why?
|
Heroin Dependence | 2 | 2013 | 175 | 0.830 |
Why?
|
Dyskinesias | 1 | 2021 | 78 | 0.750 |
Why?
|
Tryptophan Hydroxylase | 1 | 2020 | 89 | 0.730 |
Why?
|
Amidohydrolases | 3 | 2018 | 169 | 0.710 |
Why?
|
Nuclear Physics | 6 | 2014 | 79 | 0.690 |
Why?
|
Substance-Related Disorders | 5 | 2020 | 4258 | 0.670 |
Why?
|
Gambling | 2 | 2019 | 250 | 0.660 |
Why?
|
Child Abuse | 2 | 2023 | 1030 | 0.600 |
Why?
|
Neurosciences | 1 | 2021 | 348 | 0.560 |
Why?
|
Patient Participation | 2 | 2022 | 1457 | 0.540 |
Why?
|
Stress, Psychological | 4 | 2020 | 4245 | 0.500 |
Why?
|
Morphine | 1 | 2019 | 657 | 0.490 |
Why?
|
Cues | 2 | 2019 | 873 | 0.490 |
Why?
|
Elementary Particles | 4 | 2014 | 55 | 0.460 |
Why?
|
Tropicamide | 1 | 2013 | 23 | 0.460 |
Why?
|
Heroin | 1 | 2013 | 117 | 0.430 |
Why?
|
Women's Health | 1 | 2022 | 2034 | 0.430 |
Why?
|
Naltrexone | 1 | 2014 | 307 | 0.420 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3133 | 0.420 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3240 | 0.410 |
Why?
|
Ophthalmic Solutions | 1 | 2013 | 317 | 0.410 |
Why?
|
Dopamine | 1 | 2019 | 1591 | 0.400 |
Why?
|
Narcotic Antagonists | 1 | 2014 | 562 | 0.360 |
Why?
|
Cocaine-Related Disorders | 1 | 2013 | 460 | 0.340 |
Why?
|
Deep Brain Stimulation | 1 | 2017 | 748 | 0.340 |
Why?
|
Ethanol | 2 | 2015 | 1342 | 0.330 |
Why?
|
Substance Abuse, Intravenous | 1 | 2013 | 525 | 0.320 |
Why?
|
Clinical Trials as Topic | 2 | 2022 | 7913 | 0.310 |
Why?
|
Receptors, CCR2 | 1 | 2008 | 212 | 0.300 |
Why?
|
Models, Theoretical | 6 | 2014 | 3589 | 0.290 |
Why?
|
Endocannabinoids | 2 | 2018 | 116 | 0.280 |
Why?
|
HLA-DR Antigens | 1 | 2008 | 645 | 0.280 |
Why?
|
Pandemics | 3 | 2021 | 8388 | 0.280 |
Why?
|
Neural Pathways | 1 | 2017 | 2972 | 0.270 |
Why?
|
Touch Perception | 2 | 2017 | 114 | 0.260 |
Why?
|
Cerebral Cortex | 2 | 2018 | 5708 | 0.260 |
Why?
|
Stress Disorders, Post-Traumatic | 3 | 2018 | 4266 | 0.250 |
Why?
|
Elementary Particle Interactions | 2 | 2013 | 19 | 0.230 |
Why?
|
Sarcoidosis | 1 | 2008 | 506 | 0.220 |
Why?
|
Somatosensory Cortex | 2 | 2017 | 528 | 0.210 |
Why?
|
Infusions, Intravenous | 2 | 2019 | 2274 | 0.210 |
Why?
|
Physician-Patient Relations | 1 | 2015 | 3229 | 0.200 |
Why?
|
Mental Disorders | 1 | 2021 | 6600 | 0.190 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3843 | 0.190 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2022 | 323 | 0.180 |
Why?
|
Neurobiology | 1 | 2021 | 121 | 0.180 |
Why?
|
Drugs, Investigational | 1 | 2022 | 214 | 0.180 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2020 | 15519 | 0.180 |
Why?
|
Pulmonary Embolism | 2 | 2023 | 2376 | 0.180 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 629 | 0.170 |
Why?
|
Raclopride | 1 | 2019 | 97 | 0.170 |
Why?
|
Repression, Psychology | 1 | 2018 | 44 | 0.170 |
Why?
|
Humans | 36 | 2023 | 744343 | 0.160 |
Why?
|
Polyunsaturated Alkamides | 1 | 2018 | 29 | 0.160 |
Why?
|
Affect | 2 | 2017 | 1476 | 0.160 |
Why?
|
Brain | 5 | 2019 | 26385 | 0.160 |
Why?
|
Dopamine Antagonists | 1 | 2019 | 296 | 0.160 |
Why?
|
Blinking | 1 | 2018 | 138 | 0.160 |
Why?
|
Arachidonic Acids | 1 | 2018 | 299 | 0.160 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 841 | 0.160 |
Why?
|
Cocaine | 2 | 2022 | 1007 | 0.160 |
Why?
|
Receptors, Vasopressin | 1 | 2018 | 112 | 0.150 |
Why?
|
Carbon Radioisotopes | 1 | 2019 | 577 | 0.150 |
Why?
|
Touch | 2 | 2017 | 306 | 0.150 |
Why?
|
Social Isolation | 1 | 2020 | 365 | 0.150 |
Why?
|
Neuronavigation | 1 | 2018 | 167 | 0.150 |
Why?
|
Female | 24 | 2023 | 380194 | 0.150 |
Why?
|
Mesons | 2 | 2014 | 33 | 0.140 |
Why?
|
Sex Characteristics | 3 | 2023 | 2585 | 0.140 |
Why?
|
Sex Factors | 2 | 2021 | 10397 | 0.140 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2018 | 304 | 0.140 |
Why?
|
Prefrontal Cortex | 3 | 2022 | 2147 | 0.130 |
Why?
|
Microsatellite Repeats | 1 | 2018 | 802 | 0.130 |
Why?
|
Homozygote | 1 | 2020 | 1785 | 0.130 |
Why?
|
Alcohol Deterrents | 1 | 2015 | 39 | 0.130 |
Why?
|
Young Adult | 9 | 2019 | 56430 | 0.130 |
Why?
|
Happiness | 1 | 2016 | 170 | 0.120 |
Why?
|
Physical Stimulation | 1 | 2016 | 525 | 0.120 |
Why?
|
Neutrons | 1 | 2014 | 76 | 0.120 |
Why?
|
Cross-Over Studies | 1 | 2018 | 2029 | 0.110 |
Why?
|
Adult | 16 | 2022 | 214055 | 0.110 |
Why?
|
Risk-Taking | 1 | 2018 | 986 | 0.110 |
Why?
|
Triazines | 1 | 2015 | 315 | 0.110 |
Why?
|
Male | 18 | 2023 | 350118 | 0.110 |
Why?
|
Amygdala | 1 | 2020 | 1315 | 0.110 |
Why?
|
Photic Stimulation | 2 | 2014 | 2025 | 0.100 |
Why?
|
Gyrus Cinguli | 1 | 2017 | 1091 | 0.100 |
Why?
|
Placebo Effect | 1 | 2015 | 502 | 0.100 |
Why?
|
Morpholines | 1 | 2014 | 571 | 0.100 |
Why?
|
Gene Frequency | 3 | 2018 | 3588 | 0.090 |
Why?
|
Injections, Intravenous | 1 | 2013 | 1420 | 0.090 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2703 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 6 | 2020 | 35421 | 0.090 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2020 | 6038 | 0.090 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3647 | 0.090 |
Why?
|
Fear | 1 | 2018 | 1440 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1671 | 0.090 |
Why?
|
DNA Methylation | 1 | 2023 | 4286 | 0.080 |
Why?
|
Drug Interactions | 1 | 2013 | 1460 | 0.080 |
Why?
|
Middle Aged | 9 | 2020 | 213383 | 0.080 |
Why?
|
Case-Control Studies | 2 | 2020 | 21746 | 0.080 |
Why?
|
Haplotypes | 2 | 2018 | 2779 | 0.080 |
Why?
|
Protons | 1 | 2013 | 1127 | 0.070 |
Why?
|
Anxiety | 2 | 2023 | 4297 | 0.070 |
Why?
|
Spain | 1 | 2008 | 465 | 0.070 |
Why?
|
Environment | 1 | 2013 | 1124 | 0.070 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2012 | 1375 | 0.070 |
Why?
|
Ketamine | 1 | 2012 | 500 | 0.070 |
Why?
|
Sweden | 1 | 2008 | 1345 | 0.060 |
Why?
|
Gene Expression | 1 | 2018 | 7799 | 0.060 |
Why?
|
Pyrazoles | 1 | 2015 | 1972 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 17446 | 0.060 |
Why?
|
Brain Mapping | 1 | 2019 | 6669 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6234 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7279 | 0.050 |
Why?
|
Syndrome | 1 | 2008 | 3251 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2022 | 63114 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2022 | 12026 | 0.040 |
Why?
|
Child | 3 | 2023 | 77709 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2022 | 1590 | 0.040 |
Why?
|
Acute Disease | 1 | 2008 | 7149 | 0.040 |
Why?
|
Protective Agents | 1 | 2018 | 156 | 0.040 |
Why?
|
Neoplasms | 2 | 2023 | 21683 | 0.040 |
Why?
|
Finland | 1 | 2018 | 602 | 0.040 |
Why?
|
Extinction, Psychological | 1 | 2018 | 376 | 0.030 |
Why?
|
Impulsive Behavior | 1 | 2017 | 316 | 0.030 |
Why?
|
Receptors, Corticotropin-Releasing Hormone | 1 | 2015 | 87 | 0.030 |
Why?
|
Medicare | 2 | 2023 | 6566 | 0.030 |
Why?
|
Central Nervous System Depressants | 1 | 2015 | 167 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1071 | 0.030 |
Why?
|
Logistic Models | 1 | 2008 | 13408 | 0.030 |
Why?
|
Pregnancy | 4 | 2023 | 29144 | 0.030 |
Why?
|
Electrons | 1 | 2014 | 268 | 0.030 |
Why?
|
Genotype | 2 | 2018 | 12951 | 0.030 |
Why?
|
Emotions | 2 | 2015 | 2661 | 0.030 |
Why?
|
Thermodynamics | 1 | 2014 | 596 | 0.030 |
Why?
|
United States | 4 | 2023 | 69872 | 0.030 |
Why?
|
Aged | 4 | 2023 | 163280 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5078 | 0.020 |
Why?
|
Sleep | 1 | 2023 | 4623 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2017 | 2564 | 0.020 |
Why?
|
Animals | 3 | 2018 | 168757 | 0.020 |
Why?
|
Registries | 1 | 2022 | 8089 | 0.020 |
Why?
|
Rome | 1 | 2006 | 28 | 0.020 |
Why?
|
Visual Perception | 1 | 2015 | 1420 | 0.020 |
Why?
|
Risk Factors | 2 | 2023 | 72290 | 0.020 |
Why?
|
Prevalence | 1 | 2022 | 15226 | 0.020 |
Why?
|
Nerve Net | 1 | 2016 | 2174 | 0.010 |
Why?
|
Italy | 1 | 2006 | 832 | 0.010 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2006 | 780 | 0.010 |
Why?
|
Comorbidity | 1 | 2014 | 10388 | 0.010 |
Why?
|
Adolescent | 2 | 2018 | 85781 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10943 | 0.010 |
Why?
|
International Cooperation | 1 | 2006 | 1420 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2017 | 15540 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2018 | 12261 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15165 | 0.010 |
Why?
|
Rats | 1 | 2012 | 24260 | 0.010 |
Why?
|
Cohort Studies | 1 | 2018 | 40561 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18029 | 0.010 |
Why?
|
Mice | 1 | 2018 | 81183 | 0.010 |
Why?
|